deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT02414269

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

A Phase I/II Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Sponsor: Bellicum Pharmaceuticals

Conditions Breast Cancer Lung Cancer Malignant Pleural Disease Mesothelioma Metastases
Interventions cyclophosphamide iCasp9M28z T cell infusions pembrolizumab
Updated 24 times since 2017 Last updated: Oct 3, 2025 Started: May 31, 2015 Primary completion: Apr 30, 2026 Completion: Apr 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Breast Cancer and Lung Cancer, this trial is ongoing. The trial is conducted by Bellicum Pharmaceuticals and has accumulated 24 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Mar 2018 · 10 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Jun 2019 · 8 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Nov 2020 · 5 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Dec 2021 · 7 months · monthly snapshot~Dec 2021 – ~May 2022 · 5 months · monthly snapshot~May 2022 – ~Dec 2022 · 7 months · monthly snapshot~Dec 2022 – ~Aug 2023 · 8 months · monthly snapshot~Aug 2023 – ~May 2024 · 9 months · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Nov 2025 · 5 months · monthly snapshot~Nov 2025 – present · 10 months · monthly snapshot

Change History

24 versions recorded

  1. Nov 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Jun 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Sep 2024 — Jun 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 19 earlier versions

  1. May 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Aug 2023 — May 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Dec 2022 — Aug 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. May 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Dec 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  6. May 2021 — Dec 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jun 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

  10. Apr 2020 — Jun 2020 [monthly]

    Recruiting PHASE1_PHASE2

  11. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Phase: PHASE1 → PHASE1_PHASE2

  12. Sep 2019 — Mar 2020 [monthly]

    Recruiting PHASE1

  13. Jun 2019 — Sep 2019 [monthly]

    Recruiting PHASE1

  14. Oct 2018 — Jun 2019 [monthly]

    Recruiting PHASE1

  15. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  16. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  17. May 2017 — Mar 2018 [monthly]

    Recruiting PHASE1

  18. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE1

  19. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bellicum Pharmaceuticals
  • Memorial Sloan Kettering Cancer Center
  • United States Department of Defense
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations